regorafenib
bayer
[]
phase 3 integrate ii trial data presented at #gi23 shows regorafenib is a new therapeutic option in refractory metastatic gastric and junctional adenocarcinoma 
Academic GI Cancer Centre in the City of London. Delivering evidence-based treatments and clinical trials to patients. Informing and education patients and HCPs